




RealRate

PHARMACEUTICAL 2014

Supernus Pharmaceuticals INC
Rank 173 of 234



The relative strengths and weaknesses of Supernus Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Supernus Pharmaceuticals INC compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 1.1% points. The greatest weakness of Supernus Pharmaceuticals INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 59% points.

The company's Economic Capital Ratio, given in the ranking table, is 141%, being 102% points below the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	97,161
Cost of Goods Sold	0
Intangible Assets	1,158
Liabilities, Current	26,400
Liabilities, Non-Current	2,677
Other Assets	10,122
Other Compr. Net Income	57
Other Expenses	1,104
Other Liabilities	48,454
Other Net Income	-30,353
Other Revenues	12,019
Property and Equipment	2,554
Research and Development	17,245
Selling, General and Administrative Expense	55,590

Output Variable	Value in 1000 USD
Assets	110,995
Liabilities	77,531
Expenses	73,939
Revenues	12,019
Stockholders Equity	33,464
Net Income	-92,273
Comprehensive Net Income	-92,244
BaseVar	152,447
ECR before LimitedLiability	-20%
Economic Capital Ratio	141%